$8.22
+0.72 (+9.60%)
Open$7.65
Previous Close$7.50
Day High$8.40
Day Low$7.65
52W High$35.11
52W Low$18.59
Volume—
Avg Volume640.0K
Market Cap33.25M
P/E Ratio19.88
EPS$1.45
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+288.2% upside
Current
$8.22
$8.22
Target
$31.91
$31.91
$24.67
$31.91 avg
$44.05
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 6.10M | 5.44M | 5.56M |
| Net Income | -1,470,070 | -1,283,535 | -1,495,769 |
| Profit Margin | -24.1% | -23.6% | -26.9% |
| EBITDA | -2,132,580 | -2,024,078 | -1,912,875 |
| Free Cash Flow | -1,039,733 | -1,099,827 | -902,858 |
| Rev Growth | +9.0% | +18.0% | +2.0% |
| Debt/Equity | 0.62 | 0.45 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |